2024
Racial Differences in 1-Year Mortality after Hospitalization for Chronic Obstructive Pulmonary Disease in the United States.
Jain S, Priya A, Pekow P, Spitzer K, Walkey A, Opara I, Krumholz H, Lindenauer P. Racial Differences in 1-Year Mortality after Hospitalization for Chronic Obstructive Pulmonary Disease in the United States. Annals Of The American Thoracic Society 2024, 21: 585-594. PMID: 37943953, PMCID: PMC10995557, DOI: 10.1513/annalsats.202304-359oc.Peer-Reviewed Original ResearchChronic obstructive pulmonary diseaseChronic obstructive pulmonary disease hospitalizationsObstructive pulmonary diseaseMedicare beneficiariesWhite racePulmonary diseaseChronic obstructive pulmonary disease exacerbationsChronic obstructive pulmonary disease patientsObstructive pulmonary disease exacerbationsObstructive pulmonary disease patientsHospital-level clusteringPulmonary disease exacerbationsRetrospective cohort studyPulmonary disease patientsCox regression modelIndividual socioeconomic statusDisease exacerbationPulmonary rehabilitationCohort studyDischarge dispositionOverall mortalityIllness severityHospitalized populationCare factorsDisease patients
2022
Gene Sequencing Identifies Perturbation in Nitric Oxide Signaling as a Nonlipid Molecular Subtype of Coronary Artery Disease
Khera AV, Wang M, Chaffin M, Emdin CA, Samani NJ, Schunkert H, Watkins H, McPherson R, Erdmann J, Elosua R, Boerwinkle E, Ardissino D, Butterworth A, Di Angelantonio E, Naheed A, Danesh J, Chowdhury R, Krumholz H, Sheu W, Rich S, Rotter J, Chen Y, Gabriel S, Lander E, Saleheen D, Kathiresan S. Gene Sequencing Identifies Perturbation in Nitric Oxide Signaling as a Nonlipid Molecular Subtype of Coronary Artery Disease. Circulation Genomic And Precision Medicine 2022, 15: e003598. PMID: 36215124, PMCID: PMC9771961, DOI: 10.1161/circgen.121.003598.Peer-Reviewed Original ResearchConceptsMolecular subtypesCAD riskHigher systolic blood pressureCoronary artery disease patientsEndothelial nitric oxide synthase geneDamaging missense variantsRisk of CADSystolic blood pressureCoronary artery diseaseRisk of hypertensionNitric oxide synthase geneMissense variantsNitric oxide synthesisRare variantsOxide synthase geneDiscrete molecular subtypesNitric Oxide SignalingLow density lipoprotein receptor geneArtery diseaseBlood pressureEndothelial functionVascular toneDisease patientsCAD casesCholesterol concentrations
2011
Investigation of 95 variants identified in a genome-wide study for association with mortality after acute coronary syndrome
Morgan TM, House JA, Cresci S, Jones P, Allayee H, Hazen SL, Patel Y, Patel RS, Eapen DJ, Waddy SP, Quyyumi AA, Kleber ME, März W, Winkelmann BR, Boehm BO, Krumholz HM, Spertus JA. Investigation of 95 variants identified in a genome-wide study for association with mortality after acute coronary syndrome. BMC Medical Genomics 2011, 12: 127. PMID: 21957892, PMCID: PMC3190329, DOI: 10.1186/1471-2350-12-127.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAged, 80 and overAminohydrolasesCohort StudiesFemaleFormate-Tetrahydrofolate LigaseGenetic VariationGenome-Wide Association StudyGenotypeHumansKaplan-Meier EstimateMaleMethylenetetrahydrofolate Dehydrogenase (NADP)Middle AgedMultienzyme ComplexesMyocardial InfarctionPolymorphism, Single NucleotideProportional Hazards ModelsRisk FactorsWhite PeopleConceptsAcute coronary syndromeCoronary syndromeCoronary artery disease patientsKaplan-Meier survival analysisACS risk factorsCoronary artery diseaseUniversity-affiliated hospitalMyocardial infarction patientsPremature myocardial infarctionRace-adjusted analysesACS mortalityArtery diseaseCox regressionBorderline significanceDisease patientsInfarction patientsMyocardial infarctionRisk factorsMortality hazardIndependent cohortSurvival analysisDiverse cohortPatientsRelevant covariatesBackgroundGenome-wide association studies
2003
Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction
Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. Journal Of The American College Of Cardiology 2003, 42: 201-208. PMID: 12875751, DOI: 10.1016/s0735-1097(03)00572-2.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAnalysis of VarianceAngiotensin-Converting Enzyme InhibitorsAspirinCase-Control StudiesCohort StudiesDrug Therapy, CombinationDrug UtilizationFemaleHumansKidney Failure, ChronicLogistic ModelsMaleMyocardial InfarctionPatient SelectionPeritoneal DialysisPlatelet Aggregation InhibitorsPractice Patterns, Physicians'PrognosisRenal DialysisRisk FactorsSurvival AnalysisTreatment OutcomeUnited StatesConceptsEnd-stage renal diseaseNon-ESRD patientsAcute myocardial infarctionESRD patientsRenal diseaseMyocardial infarctionAngiotensin-converting enzyme inhibitor therapyEnd-stage renal disease patientsAngiotensin-converting enzyme inhibitorStandard medical therapyEnzyme inhibitor therapyRenal disease patientsCooperative Cardiovascular Project databaseHigh-risk populationLogistic regression modelsEarly administrationInhibitor therapyMedical therapyACE inhibitorsAMI patientsPeritoneal dialysisPoor prognosisDisease patientsESRD databasePatients